Story
Genfit Stock Gains on Strong Royalty Growth, Upgraded Iqirvo® Sales Forecast
Summary
Shares of the biopharmaceutical company rose after its first-half results showed surging royalty revenues and its partner, Ipsen, doubled the peak sales forecast for the liver disease drug Iqirvo®.
Shares of Genfit (GNFT) climbed 1.3% to €9.97 in recent trading after the company reported strong first-half 2026 financial results, highlighted by accelerating royalty income and a significantly improved commercial outlook from its partner, Ipsen.
Strong H1 Results and Upgraded Outlook
Genfit announced first-half revenues of €21.1 million, sourced almost entirely from royalties on its liver disease drug Iqirvo® (elafibranor) under a licensing agreement with Ipsen. The company also reported a solid balance sheet with €113.8 million in cash and equivalents, providing a financial runway that it states extends beyond the end of 2028.
Investor sentiment was further bolstered by Ipsen's decision to double its peak annual global sales forecast for Iqirvo® in primary biliary cholangitis to €1 billion. This upgrade directly increases the potential long-term value of the royalty stream for Genfit. CEO Pascal Prigent noted that "Iqirvo® continues to perform above expectations, with royalty revenue more than tripling in the first half of 2026 compared with the same period last year."
Diagnostic and Market Catalysts
AdBeyond its drug pipeline, Genfit confirmed that its non-invasive MASH diagnostic test, NASHnext®, has secured U.S. Medicare coverage. The test is commercialized by Labcorp, and independent projections cited by the company suggest peak U.S. sales of related products could surpass $1.5 billion by 2033.
The stock's performance is also supported by its recent inclusion in the CAC Mid 60 and SBF 120 indices in mid-September. Such index additions often attract increased buying from passive and institutional funds that track these benchmarks.
Market Context
The move in Genfit's stock appears to be driven by company-specific news rather than a broader market trend. Major U.S. equity indices were little changed, with the S&P 500 up just 0.1%, indicating that investors were reacting directly to the combination of a strong cash position, accelerating revenues, and positive pipeline developments.
Read next
More on Stocks
Tesla Secures Approval for Full Self-Driving Software in Croatia
Tesla announced it has received regulatory approval to launch its supervised Full Self-Driving software in Croatia, marking another step in its European expansion plans ahead of a potential EU-wide decision.
Aéroports de Paris Shares Fall on French Proposal to Hike Infrastructure Tax
Shares in Paris airport operator Aéroports de Paris (ADP) dropped after the French government proposed a significant increase to a tax on transport infrastructure, a measure expected to raise an additional €800 million annually.
UK Unsecured Lending Hits Record Pace as Mortgage Approvals Fall
British households increased their unsecured borrowing at the fastest annual rate on record in August, according to Bank of England data, while mortgage approvals for home purchases fell to an eight-month low.
Egetis Therapeutics Stock Hits 52-Week High on FDA Approval for Rare Disease Drug
Shares of the Swedish biotech company surged over 13% after its drug, Emcitate, received U.S. Food and Drug Administration approval, becoming the first sanctioned treatment for the rare genetic disorder MCT8 deficiency.